Adderall significantly increased BP and heart rate among healthy young adults who never previously used the medication, simulating its effects among those who may abuse it recreationally, researchers ...

EXCLUSIVE: Americans who suffered devastating side effects after taking GLP-1 drugs Ozempic and Wegovy tell Rhian Lubin why they are suing. “If someone would have told me ... a drug I was taking could ...

Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...

AstraZeneca executives have told Fierce Biotech they still see potential in harnessing the relaxin hormone to treat heart failure despite abandoning work on one of two clinical-stage candidates. As ...

Fans watching the Winter Olympics on NBC networks may notice a unique addition to the coverage—a live heart rate monitor showing the stress of the coaches, parents and partners of the American ...

Beta blockers represent an important class of antihypertensive agents, but comparative data on different beta blockers in the treatment of hypertension remain limited. Nebivolol, a third‐generation ...

While current clinical trials for cardiac regeneration using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) employ immunosuppressive regimens used in heart transplants, the precise ...

James is a published author with multiple pop-history and science books to his name. He specializes in history, space, strange science, and anything out of the ordinary.View full profile James is a ...

If you're one of tens of millions of Americans on a GLP-1 weight loss drug, you know how effective they can be. Now, an even more powerful drug is on the horizon from pharmaceutical company Eli Lilly.

Jan 19 (Reuters) - Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable tablet, as the first drug to delay congestive heart ...

Cytokinetics Inc. won US approval for a drug to treat a deadly heart condition, posing a potential threat to sales of a similar Bristol Myers Squibb Co. treatment that’s expected to be a key growth ...